ATG Plus Low-dose PT-Cy for GVHD Prevention

Stopped DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.

Conditions

• Hematologic Malignancy

Interventions

• DRUG: Cyclophosphamid
• DRUG: ATG

Sponsor

Peking University People's Hospital